CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

Blood

Volumn 102, Issue 9, 2003, Pages 3093-3096

  Pardanani, Animesh ^b   Ketterling, Rhett P ^b   Brockman, Stephanie R ^b   Flynn, Heather C ^b   Paternoster, Sarah F ^b   Shearer, Brandon M ^b   Reeder, Terra L ^b   Li, Chin Yang ^b   Cross, Nicholas C P ^b   Cools, Jan ^b   Gilliland, D Gary ^b   Dewald, Gordon W ^b   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; VALINE;

ABL GENE; ADULT; AGED; ARTICLE; BONE MARROW CELL; CHIC2 GENE; CHROMOSOME 4Q; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG ACTIVITY; EOSINOPHIL; EOSINOPHILIA; FIP1L1 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE FUSION; GENE LOCUS; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPEREOSINOPHILIC SYNDROME; MAST CELL; MASTOCYTOSIS; MONONUCLEAR CELL; NEUTROPHIL; NUCLEOTIDE SEQUENCE; ONCOGENE; PATHOGENESIS; PDGFRA GENE; PDGFRB GENE; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC DISEASE;

EID: 10744228486     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1627     Document Type: Article

References (25)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
2. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344:1038-1042.
3. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054-5058.
4. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
5. Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed. 2001;3:9.
6. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002;26:881-884.
7. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359:1577-1578.
8. Pardanani AD, Reeder TL, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003;101: 3391-3397.
9. Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101: 4714-4716.
10. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
11. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481-487.
12. Pardanani A, Baek JY, Li CY, Butterfield JH, Tefferi A. Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study. Mayo Clin Proc. 2002;77:1169-1175.
13. Furitsu T, Tsuiimura T, Tono T, et al. Identification of mutations in the coding sequence of the protooncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest. 1993;92:1736-1744.
14. Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD, Gralnick HR. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med. 1991;91:612-624.
15. Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG. Systemic mast cell disease: analysis of 58 cases and literature review. Medicine (Baltimore). 1988;67:345-368.
16. Horny HP, Parwaresch MR, Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol. 1985;16:808-814.
17. Pardanani AD, Elliott MA, Reeder TL, et al. Imatinib therapy for systemic mast cell disease. Lancet. 2003;362:535-537.
18. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603-625.
19. Pardanani A, Reeder TL, Kimlinger TK, et al. Flt-3 and c-kit mutations studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res. 2003;27:739-742.
20. Pardanani A, Reeder T, Li C-Y, Tefferi A. Eosinophils are derived from the neoplastic clone in systemic mast cell disease. Leuk Res. 2003;27:883-885.
21. Spurbeck JL, Carlson RO, Allen JE, Dewald GW. Culturing and robotic harvesting of bone marrow, lymph nodes, peripheral blood, fibroblasts, and solid tumors with in situ techniques. Cancer Genet Cytogenet. 1988;32:59-66.
22. Dewald GW. Interphase FISH studies of chronic myeloid leukemia. Methods Mol Biol. 2002;204: 311-342.
23. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101:4660-4666.
24. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.
25. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99:1741-1744.